Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference30 articles.
1. Angelini J, Talotta R, Roncato R, et al. JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10(7):1002.
2. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.
3. Ciobanu DA, Poenariu IS, Crîngus L-I, et al. JAK/STAT pathway in pathology of rheumatoid arthritis. Exp Ther Med. 2020;20(4):3498–503.
4. Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–46.
5. European Medicines Agency. Filgotinib (Jyseleca): EU summary of product characteristics. 2020. https://www.ema.europa.eu/. Accessed 18 May 2021.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献